Gubra
Business Services · Denmark · 51-200 Employees
View Company Info for Free
Overview
Headquarters
Hørsholm Kongevej 11b, Korsholm, North D...Phone Number
+45 31522650Website
www.gubra.dkRevenue
$6.3 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Gubra
Gubra specializes in high-end preclinical contract research and peptide-based drug discovery, focusing on metabolic and fibrotic diseases. Their services include advanced modeling and technologies for drug development, particularly in areas such as obesity, diabetes, and kidney diseases. Gubra partners with various organizations to enhance drug discovery and development, leveraging their expertise in peptide therapeutics. The company is committed to sustainability and invests in green initiatives to contribute to a more sustainable future.Explore more
Gubra Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Gubra your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at Gubra
Click to see if Gubra had a recent Job posting/layoffs
Check if Gubra has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once Gubra has new funding data
Check out if Gubra is spiking on competitors!
Product Launch: Get notified when Gubra launches new products
Website visits: Recent activity has been detected on your website
Gubra, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on Gubra recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Company Profile Activity
Activity Insights
Gubra is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Gubra is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Gubra.
Gubra Tech Stack
A closer look at the technologies used by Gubra
See more technologies
Most Recent Scoops
Project
Gubra has comprehensively characterized Gubra UCN2, a 38 amino acid peptide engineered for high CRH receptor-2 selectivity and once-weekly subcutaneous administration, in preclinical studies demonstrating selective fat mass reduction and preservation of lean mass, including an additive effect on fat mass reduction when co-administered with semaglutide in diet-induced obese rat models.
Project
plans to execute a Phase 1 to Phase 2A clinical trial for Gubra UCN2 in approximately 188 participants, evaluating safety, tolerability, and initial efficacy on muscle volume and muscle function as monotherapy or in combination with incretin-based therapy.
Medical Research, Pharmaceuticals, Clinical Operations
Project
Gubra has announced that its Gubra UCN2 clinical trial application is currently under review by the German Federal Institute for Drugs and Medical Devices (BfArM) and the associated ethics committee, with clarifying questions being addressed, and the company anticipates approval in time for trial initiation in the second half of 2026.
Clinical Operations
Project
Gubra is planning to enter clinical development for Gubra UCN2 in the second half of 2026, targeting obesity drug-induced muscle loss as the first indication, with potential expansion into metabolic and cardiorenal indications based on preclinical findings related to insulin sensitivity, glucose homeostasis, and cardiac and renal function.
Medical Research, Pharmaceuticals, Clinical Operations
Project
Product Development, Medical Research
Gubra News & Media
Gubra re-elects board of directors - MedWatch
Monika Lessl will thus continue as chair of the Danish biotech company.Gubra recruits former Novo Nordisk director as new CTO - MedWatch
Gubra’s new chief technology officer was until recently senior director at Novo Nordisk.Denmark: Abbvie enters obesity field with license agreement with Gubra
Denmark: Abbvie enters obesity field with license agreement with GubraAbbVie and Gubra Announce License Agreement to Develop an Amylin Analog for the Treatment of Obesity
Partnership marks AbbVie's entrance into the obesity field Agreement will enable the incorporation of GUB014295, an amylin peptide discovered and developed by Gubra, into AbbVie's global infrastructure for developing and commercializing therapies for patients in need NORTH CHICAGO, Ill....
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Frequently Asked Questions Regarding Gubra
Sign Up For FreeTo access detailed company insights
Gubra specializes in high-end preclinical contract research and peptide-based drug discovery, focusing on metabolic and fibrotic diseases. Their services include advanced modeling and technologies for drug development, particularly in areas such as obesity, diabetes, and kidney diseases. Gubra partners with various organizations to enhance drug dis... Read More
